Morningstar

Lexicon Pharmaceuticals Inc LXRX

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

GlobeNewswire Sep 27, 2024 12:00pm
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

GlobeNewswire Sep 16, 2024 12:00pm
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

GlobeNewswire Sep 10, 2024 12:00pm
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

GlobeNewswire Sep 3, 2024 8:00pm
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

GlobeNewswire Sep 3, 2024 12:00pm
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

GlobeNewswire Aug 21, 2024 12:00pm
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

GlobeNewswire Aug 13, 2024 12:30pm
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

GlobeNewswire Aug 7, 2024 12:00pm
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire Aug 1, 2024 8:00pm
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

GlobeNewswire Jul 25, 2024 12:00pm
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

GlobeNewswire Jul 16, 2024 12:00pm
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

GlobeNewswire Jul 15, 2024 12:00pm
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin

Global News Select Mar 11, 2024 12:57pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.